Characterization of influenza virus variants induced by treatment with the endonuclease inhibitor baloxavir marboxil.
Omoto S, Speranzini V, Hashimoto T, Noshi T, Yamaguchi H, Kawai M, Kawaguchi K, Uehara T, Shishido T, Naito A, Cusack S. · 2018
Read Characterization of influenza virus variants induced by treatment with the endonuclease inhibitor baloxavir marboxil. by Omoto S, Speranzini V, Hashimoto T, Noshi T, Yamaguchi H, Kawai M, Kawaguchi K, Uehara T, Shishido T, Naito A, Cusack S. (2018) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc6018108.txt.
Introduction
Omoto and co-authors study influenza variants linked to a new drug. Their research article appeared in Scientific Reports. The drug is baloxavir marboxil, taken as a single dose. Its active form blocks a viral endonuclease enzyme. That enzyme helps influenza copy itself in infected cells.
The team examined variant viruses found after treatment in trials. A change called PA I38T stood out. It cut drug susceptibility sharply in influenza A and B. Yet the variant viruses also grew poorly in cells. Crystal structures show why the drug binds less well. The authors report markers that can guide future monitoring. Clinicians can watch for this change in treated patients.
Catalog record
| CREATOR | Omoto S, Speranzini V, Hashimoto T, Noshi T, Yamaguchi H, Kawai M, Kawaguchi K, Uehara T, Shishido T, Naito A, Cusack S. |
|---|---|
| YEAR | 2018 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 63 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Characterization of influenza virus variants induced by treatment with the endonuclease inhibitor baloxavir marboxil By Shinya Omoto, Valentina Speranzini, Takashi Hashimoto, Takeshi Noshi, Hiroto Yamaguchi, Makoto Kawai, Keiko Kawaguchi, Takeki Uehara, Takao Shishido, Akira Naito, Stephen Cusack Published in: Scientific Reports DOI: 10.1038/s41598-018-27890-4 ABSTRACT Baloxavir acid (BXA), derived from the prodrug baloxavir marboxil (BXM), potently and selectively inhibits the cap-dependent endonuclease within the polymerase PA subunit of influenza A and B viruses. In clinical trials, single doses of BXM profoundly decrease viral titers as well as alleviating influenza symptoms. Here, we characterize the impact on BXA susceptibility and replicative capacity of variant viruses detected in the post-treatment monitoring of the clinical studies. We find that the PA I38T substitution is a major pathway for reduced susceptibility to BXA, with 30- to 50-fold and 7-fold EC50 changes in A and B viruses, respectively. The viruses harboring the I38T substitution show severely impaired replicative fitness in cells, and correspondingly reduced endonuclease activity in vitro. Co-crystal structures of wild-type and I38T influenza A and B endonucleases bound to BXA show that the mutation reduces van der Waals contacts with the inhibitor. A reduced affinity to the I38T mutant is supported by the lower stability of the BXA-bound endonuclease. These mechanistic insights provide markers for future surveillance of treated populations. INTRODUCTION Influenza virus causes an infectious disease annually associated with 290,000 to 650,000 deaths and 3 to 5 million cases of severe illness worldwide1. In addition, pandemics, caused by newly emerging reassortment viruses, can have a devastating impact globally. Therefore, continued efforts are necessary to improve vaccines and anti-viral drugs as countermeasures2. Two classes of antivirals are currently available for clinical use, neuraminidase inhibitors (NAIs: oseltamivir, zanamivir, peramivir) and M2 ion-channel inhibitors (amantadine, rimantadine). However, circulating influenza viruses are now largely resistant to the M2 inhibitors3. Moreover, the antiviral potency of the NAIs is relatively moderate4–7, and another concern for this class of drugs is the emergence of resistance, as occurred during the 2008 to 2009 season when oseltamivir-resistant H1N1 was prevalent8. Therefore, more effective antiviral agents, with a novel mechanism of action, are required for the treatment and prevention of influenza virus infections. The heterotrimeric RNA-dependent RNA polymerase (RdRp) of influenza virus is composed of subunits PA, PB1 and PB2. It is responsible for replication and transcription of the segmented, single-stranded viral RNA genome (vRNA) in the nucleus of infected cells9,10. Transcription of viral mRNAs occurs through a unique “cap-snatching” mechanism. This involves high-jacking host RNA polymerase II11,12 by binding of nascent capped transcripts to the PB2 subunit13 followed by cleavage at nucleotides 10–13 by the cap-dependent endonuclease (CEN) in the PA subunit14,15. The short, capped oligomers so generated serve as primers for transcription of viral mRNA by the RdRp function of the PB1 subunit16,17. The viral transcripts are poly-adenylated by a stuttering mechanism at a conserved U-rich region of the template vRNA for translation to functional proteins after nuclear export18. Since cap-snatching is essential for virus replication, the cap-binding19, endonuclease20,21 and RdRp activities are all attractive targets for small molecule inhibitors22, and indeed several novel compounds targeting the polymerase are under active clinical development23. Favipiravir (Avigan), an RNA synthesis inhibitor, was approved in Japan in 2014 although the indication is limited for treatment of novel influenza viruses unresponsive to other agents24. Pimodivir (JNJ-63623872, VX-787), a PB2 cap-binding inhibitor, has demonstrated virological efficacy alone and in combination with oseltamivir in uncomplicated influenza, but is only active against influenza A viruses25,26. Therefore, continued efforts to discover and develop influenza drugs with improved properties are still required. As an alternative approach to influenza therapeutics, we developed baloxavir acid (S-033447; BXA) and its prodrug baloxavir marboxil (S-033188; BXM), in which a phenolic hydroxyl group was added to enhance oral absorption of BXA (Fig. 1). BXA was developed by rational molecular design based on the two-metal pharmacophore concept for dolutegravir (DTG), a strand transfer inhibitor of human immunodeficiency virus (HIV) integrase27. Both CEN and HIV integrase use two divalent metal ions as cofactors for their endonuclease activities. Since DTG binds to these ions in the HIV integrase active site, we proposed that the metal-chelating chemical scaffold of DTG could also be used for the development of CEN inhibitors. We initially screened metal-chelating compounds by CEN enzymatic assays, followed by a cellular phenotypic screen and then optimized the chemical structure to improve the pharmacokinetics and safety. This culminated in the generation of the compounds BXA and BXM that target the CEN in the PA proteins of influenza A and B viruses23,28. Because amino acids (AAs) in the active site of CEN are well conserved across seasonal, pandemic, and highly pathogenic avian influenza viruses14,15, BXA/BXM has the potential to be a new broad-spectrum, therapeutic class of anti-influenza therapy. Whereas single doses of BXM achieved a profound decline in viral titers of swabs, resulting in alleviation of influenza symptoms in uncomplicated influenza in clinical studies23,28, information on the mechanism of BXA binding to PA and potential determinants for reduced susceptibility are limited. Here, we report AA substitutions detected in the clinical studies of BXM and the impact they have on drug susceptibility and viral replicative capacity. To understand better the molecular mechanisms involved, we determined the co-crystal structures of wild-type and I38T endonuclease domains from influenza A and B viruses with bound BXA. Our virological and structural results highlight the importance of substitutions at PA residue Ile38 in the mechanism of reduced sensitivity to BXM and BXA.Figure 1Chemical structure of baloxavir acid (BXA, active form) and baloxavir marboxil (prodrug form). The full chemical name of BXA is (12aR)-12-[(11 S)-7,8-difluoro-6,11-dihydrodibenzo[b,e] thiepin-11-yl]-7-hydroxy-3,4,12,12a-tetrahydro-1H-[1,4] oxazino[3,4-c]pyrido[2,1-f][1,2,4]triazine-6,8-dione. RESULTS Resistance monitoring in phase 2 and pediatric studies of baloxavir marboxil A multi-center, randomized, double-blind, controlled phase 2 study was conducted during the 2015-6 influenza seasons with BXM in Japanese adults aged 20–64 years with uncomplicated influenza (Japic CTI-153090). In the subsequent 2016-7 influenza seasons, an open-label study was conducted with BXM in otherwise healthy pediatric patients aged 6 months to <12 years with uncomplicated influenza (Japic CTI-163417). In the clinical trials, baseline variant monitoring was conducted to evaluate BXA susceptibility of the viruses in the baseline samples from nasopharyngeal/pharyngeal swabs. In addition, monitoring was performed in paired pre- and last positive swab samples from BXM treated patients to identify treatment-emergent AA substitutions that were associated with reduced susceptibility to BXA. In order to investigate the impact of the substitutions, reverse genetics was employed to generate the recombinant variant viruses in the corresponding influenza type/subtype, followed by drug sensitivity testing by means of plaque reduction with BXA and favipiravir or NA inhibition assays with oseltamivir acid (Table 1).Table 1Drug susceptibility of the recombinant viruses with amino acid substitutions to baloxavir acid, favipiravir and oseltamivir acid.StrainsBaloxavir acidFavipiravirOseltamivir acidEC50 (nmol/L)FCEC50 (nmol/L)FCIC50 (nmol/L)FCMeanSDMeanSDMeanSD Experiment 1 rgA/WSN/33 (H1N1)0.420.12N/A17382.989432.24N/A0.800.09N/ArgA/WSN/33-NA/H274Y0.320.060.7711935.971201.470.69181.655.13 226.12 rgA/WSN/33-PA/A36V1.500.373.5920707.8514012.811.190.870.051.08rgA/WSN/33-PA/V545T0.310.110.7312579.07707.100.720.800.060.99rgA/WSN/33-PA/I38T11.371.85 27.24 7368.131531.620.420.800.011.00rgA/WSN/33-PA/I38F4.431.95 10.61 11254.263068.200.650.910.031.13rgA/WSN/33-PA/A20S0.500.271.1912837.881190.520.740.830.101.04rgA/WSN/33-PA/A20S + I38T11.432.60 27.38 7995.781798.030.460.780.050.97rgA/WSN/33-PA/A20S + I38F3.381.168.109683.283488.790.560.780.090.97rgA/WSN/33-PA/E23K1.980.484.748941.882288.510.510.860.131.07rgA/WSN/33-PA/E119D2.701.506.469404.404090.350.540.850.091.05rgA/Victoria/3/75 (H3N2)1.130.51N/A8761.262968.09N/A0.130.02N/ArgA/Victoria/3/75-PA/A36V6.872.766.099023.053510.611.030.160.011.16rgA/Victoria/3/75-PA/I38T63.803.40 56.59 5639.462773.000.640.160.011.21rgA/Victoria/3/75-PA/I38F22.6910.82 20.13 9361.514923.511.070.140.011.06rgA/Victoria/3/75-PA/E23K6.202.865.505153.403832.480.590.170.011.27rgA/Victoria/3/75-PA/E119D5.092.484.514667.202395.220.530.140.011.02rgB/Maryland/1/5910.735.52N/A15696.097234.11N/A5.471.00N/ArgB/Maryland/1/59-PA/F36A8.460.880.7921918.2715052.471.404.710.860.86rgB/Maryland/1/59-PA/F36V8.603.170.8029606.2112712.421.895.190.220.95rgB/Maryland/1/59-PA/I38T61.799.175.7621815.7013293.261.395.350.510.98rgB/Maryland/1/59-PA/I38F25.590.542.399611.083751.960.616.451.311.18rgB/Maryland/1/59-PA/E23K8.730.560.8121503.0513645.361.376.561.321.20rgB/Maryland/1/59-PA/G548R12.171.881.1321505.259818.441.377.170.641.31rgB/Maryland/1/59-PA/E120D21.1011.061.9713337.461074.990.856.980.371.28 Experiment 2 rgA/WSN/33 (H1N1)0.310.11N/A12151.202034.53N/A0.930.10N/ArgA/WSN/33-NA/H274YN/TN/TN/TN/TN/TN/T194.1336.42 207.66 rgA/WSN/33-PA/I38M4.071.84 13.15 20150.5314005.921.660.960.081.03rgA/Victoria/3/75 (H3N2)0.830.28N/A8625.243478.51N/A0.140.02N/ArgA/Victoria/3/75-PA/L28P2.150.132.588454.414055.500.980.150.021.06rgA/Victoria/3/75-PA/L28P + V63I2.400.322.888885.881085.121.030.150.021.03rgA/Victoria/3/75-PA/V63I1.440.331.7310268.052896.971.190.150.021.07rgA/Victoria/3/75-PA/R356K0.800.490.966977.991949.950.810.150.011.05rgA/Victoria/3/75-PA/A37T6.784.048.1311323.061290.511.310.150.011.07rgA/Victoria/3/75-PA/I38T40.7611.94 48.90 7868.86810.030.91N/TN/TN/TrgA/Victoria/3/75-PA/I38T + E623K35.3416.12 42.41 3651.632226.600.420.140.011.00rgA/Victoria/3/75-PA/I38M11.481.43 13.77 12489.172100.631.450.140.011.03rgA/Victoria/3/75-PA/N412D0.450.020.545438.313166.980.630.130.010.93rgA/Victoria/3/75-PA/V517A0.430.220.524861.041205.270.560.150.011.03rgA/Victoria/3/75-PA/E623K1.000.291.207324.561807.500.850.140.010.98rgA/Victoria/3/75-PA/S632P0.610.280.745111.131956.910.590.150.011.05rgA/Victoria/3/75-PA/E199G3.721.374.468508.102292.850.990.130.010.89rgB/Maryland/1/595.191.29N/A19481.734368.72N/A8.491.89N/ArgB/Maryland/1/59-PA/I38M41.7114.718.0415519.493034.460.806.480.770.76 Experiment 3 rgA/WSN/33 (H1N1)0.450.22N/A14991.681395.47N/A1.030.25N/ArgA/WSN/33-PA/I38V0.970.802.1813027.982249.520.871.050.181.02rgA/Victoria/3/75 (H3N2)1.150.59N/A9391.13695.68N/A0.120.01N/ArgA/Victoria/3/75-PA/I38V2.110.811.8311013.302541.611.170.150.011.23EC50 of baloxavir acid and favipiravir were determined by plaque reduction assay, and IC50 of oseltamivir acid was evaluated by neuraminidase inhibition assay. Data represent the mean and standard deviation (SD) of more than